Galectin Therapeutics
GALT
73 hedge funds and large institutions have $21.6M invested in Galectin Therapeutics in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 20 increasing their positions, 9 reducing their positions, and 9 closing their positions.
31,886% more call options, than puts
Call options by funds: $2.24M | Put options by funds: $7K
156% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 9
122% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 9
24% more funds holding
Funds holding: 59 → 73 (+14)
19% more capital invested
Capital invested by funds: $18.2M → $21.6M (+$3.4M)
3% more ownership
Funds ownership: 12.32% → 15.32% (+3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.59M |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$1.12M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$834K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$414K |
| 5 |
State Street
Boston,
Massachusetts
|
+$207K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$479K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$422K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$165K |
| 4 |
Jane Street
New York
|
-$87.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$72K |
GALT Hedge Fund Activity: Q2 2024 in Review
73 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2024, worth a combined $21.6M — up 19% from $18.2M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new GALT positions and 9 closed out — a net gain of 14 holders — while 20 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $2.59M. The largest seller was Susquehanna International Group, cutting an estimated $479K.
- 73 institutional investors held Galectin Therapeutics (GALT) as of Q2 2024, up from 59 in Q1 2024.
- Funds reported $21.6M of Galectin Therapeutics stock for Q2 2024, up 19% quarter-over-quarter.
- 23 funds opened new Galectin Therapeutics positions in Q2 2024 and 9 closed out, a net change of +14 holders.
- The largest Galectin Therapeutics buyer in Q2 2024 was BlackRock, an estimated $2.59M added.
- The largest Galectin Therapeutics seller in Q2 2024 was Susquehanna International Group, an estimated $479K sold.
Based on aggregated 13F filings for Q2 2024.